NLRP3 and heart failure: CY‐09 and MCC950 (http://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=immuno%26ligandId=10057#immuno) are shown to have significant therapeutic effects in NLRP3‐driven diseases,61 MCC950 (http://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=immuno%26ligandId=8228#immuno) has the potential to block NLRP3‐induced events and there is evidence that dapansutrile (http://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=immuno%26ligandId=10056) is a clinical lead for autoinflammatory disease and heart failure.